AI brief of an SEC Form 8-K · Alnylam Pharmaceuticals (ALNY)

Alnylam Q4 revenue rises 85% to $1.1 billion; GAAP net income $111.5 million

Positive Impact 3 of 5 earnings Written later

Alnylam reported fourth quarter 2025 total revenues of $1.1 billion, up 85% from a year earlier, and GAAP net income of $111.5 million, compared with a net loss of $83.8 million in the same quarter of 2024. For the full year, total revenues were $3.71 billion, up 65%, and GAAP net income was $313.7 million, compared with a net loss of $278.2 million in 2024. The company reiterated its 2026 total net product revenue guidance of $4.9 billion to $5.3 billion.

Key points

  • Q4 2025 total net product revenues were $995 million, up 121%, led by AMVUTTRA at $827 million.
  • Full-year 2025 GAAP net income was $313.7 million, versus a net loss of $278.2 million in 2024.
  • 2026 total net product revenue guidance of $4,900 million to $5,300 million was reiterated.
  • Cash, cash equivalents and marketable securities were $2.91 billion as of December 31, 2025.

The filing

CompanyAlnylam Pharmaceuticals (ALNY)
Form8-K, current report
Filed with the SECFeb 12, 2026, 8:05 AM ET
Accession number0001628280-26-007491

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.